title: Second-wave protease inhibitors: choosing an heir.
abstract: Infection with the hepatitis C virus (HCV) is a major cause of chronic liver disease and a leading indication of liver transplantations worldwide. The current standard of care for chronic hepatitis C is a combination of pegylated interferon-α and ribavirin that is effective in slightly more than half of cases and is associated with significant side effects. The first directly acting antivirals recently reached the US market, but will have shortcomings that should in part be overcome by the second-wave PIs that are in development. This article gives an overview of the compounds that will soon be available.
authors.affiliation: Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 30625 Hannover, Germany.
authors.forename: Sandra
authors.initials: S
authors.lastname: Ciesek
authors.forename: Thomas
authors.initials: T
authors.lastname: von Hahn
authors.forename: Michael P
authors.initials: MP
authors.lastname: Manns
mesh_terms: D000621:Aminoisobutyric Acids; D000998:Antiviral Agents / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000037:antagonists & inhibitors; D003521:Cyclopropanes; D006526:Hepatitis C / Q000188:drug therapy*; D006575:Heterocyclic Compounds, 3-Ring / Q000627:therapeutic use; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D054833:Isoindoles; D007769:Lactams / Q000627:therapeutic use; D047029:Lactams, Macrocyclic; D007930:Leucine / Q000031:analogs & derivatives; D009842:Oligopeptides / Q000627:therapeutic use; D011392:Proline / Q000031:analogs & derivatives / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011804:Quinolines; D000069616:Simeprevir; D013449:Sulfonamides / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases
chemical_list: D000621:Aminoisobutyric Acids; D000998:Antiviral Agents; D002352:Carrier Proteins; D003521:Cyclopropanes; D006575:Heterocyclic Compounds, 3-Ring; D047908:Intracellular Signaling Peptides and Proteins; D054833:Isoindoles; D007769:Lactams; D047029:Lactams, Macrocyclic; D007930:Leucine; D009842:Oligopeptides; D011392:Proline; D011480:Protease Inhibitors; D011804:Quinolines; D000069616:Simeprevir; D013449:Sulfonamides; D013844:Thiazoles; D017361:Viral Nonstructural Proteins; C084422:NS3 protein, hepatitis C virus; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases; C455041:NS4A cofactor peptide, Hepatitis C virus; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; C553752:danoprevir; C552340:faldaprevir